Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of infertility, obstetrics, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ over 3200 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
We are Ferring. We believe in the power of research and the need to go where the research takes us. We believe in the value of partnership and of sharing knowledge.
We are passionate and curious about science.
We believe in medicine on the body’s own terms. We work with the body’s own endocrine systems to restore our patients’ balance and good health. We have pioneered the use of peptides and have used our knowledge to drive on into other therapy areas and other, non-peptide, treatments.